학술논문
Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?
Document Type
Academic Journal
Author
Ricci AD; Oncology Unit of National Institute of Gastroenterology - IRCCS 'Saverio de Bellis', Research Hospital Castellana Grotte, Bari, Italy.; D'Alessandro R; Laboratory of Experimental Oncology, National Institute of Gastroenterology - IRCCS 'Saverio de Bellis', Research Hospital, Castellana Grotte, Italy.; Rizzo A; Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico 'Don Tonino Bello,' I.R.C.C.S. Istituto Tumori 'Giovanni Paolo II,' Viale Orazio Flacco 65, 70124, Bari, Italy.; Schirizzi A; Laboratory of Experimental Oncology, National Institute of Gastroenterology - IRCCS 'Saverio de Bellis', Research Hospital, Castellana Grotte, Italy.; Vallarelli S; Oncology Unit of National Institute of Gastroenterology - IRCCS 'Saverio de Bellis', Research Hospital Castellana Grotte, Bari, Italy.; Ostuni C; Oncology Unit of National Institute of Gastroenterology - IRCCS 'Saverio de Bellis', Research Hospital Castellana Grotte, Bari, Italy.; Troiani L; Oncology Unit of National Institute of Gastroenterology - IRCCS 'Saverio de Bellis', Research Hospital Castellana Grotte, Bari, Italy.; Lolli IR; Oncology Unit of National Institute of Gastroenterology - IRCCS 'Saverio de Bellis', Research Hospital Castellana Grotte, Bari, Italy.; Lotesoriere C; Oncology Unit of National Institute of Gastroenterology - IRCCS 'Saverio de Bellis', Research Hospital Castellana Grotte, Bari, Italy.; Giannelli G; Scientific Direction, National Institute of Gastroenterology - IRCCS 'Saverio de Bellis', Research Hospital, Castellana Grotte, Italy.
Source
Publisher: Future Medicine Country of Publication: England NLM ID: 101485158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE
Subject
Language
English
Abstract
Following the practice-changing results observed in several hematological and solid tumors, immunotherapy with immune checkpoint inhibitors (ICIs) has been tested in cholangiocarcinoma (CCA) patients. However, ICI monotherapy has had disappointing results in CCA, and phase I-III clinical trials have assessed whether combinatorial strategies including immunotherapy plus other anticancer agents may have a synergistic activity. The TOPAZ-1 trial has recently highlighted improved survival in CCA patients receiving first-line durvalumab plus gemcitabine-cisplatin compared with gemcitabine plus cisplatin alone, and several guidelines consider adding durvalumab to the reference doublet as standard of care. This article provides an overview of durvalumab pharmacology, safety and efficacy in CCA, highlighting current and future research directions in this setting.